Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.56% | 24.14% | -208.18% | -38.12% | -6.47% |
| Total Depreciation and Amortization | 77.65% | 157.35% | 730.43% | -52.11% | -61.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 324.37% | 183.12% | 984.83% | 39.03% | -84.73% |
| Change in Net Operating Assets | 49.87% | -549.10% | 380.65% | -79.29% | -498.50% |
| Cash from Operations | 40.43% | -14.94% | -39.90% | -41.67% | -56.68% |
| Capital Expenditure | 107.37% | 64.58% | -176.06% | -4,675.56% | -2,710.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,885.81% | 155.22% | 7,522.86% | 86.68% | 97.58% |
| Cash from Investing | 1,292.50% | 154.35% | 6,548.48% | 47.83% | 96.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.98% | 220,225.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 94.52% | 96.63% | -- | -- |
| Cash from Financing | -100.01% | 94.50% | -100.19% | 216,000.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 771.93% | 72.54% | -50.20% | 43.46% | 96.76% |